(Q36705141)

15 August 2017

1 reference

title

Biochemical pharmacology and analysis of fluoropyrimidines alone and in combination with modulators (English)

1 reference

15 August 2017

1 reference

G. Weckbecker

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1721719

8 November 2022

language of work or name

1 reference

1 January 1991

1 reference

full work available at URL

15 August 2017

https://api.elsevier.com/content/article/PII:016372589190051M?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

https://api.elsevier.com/content/article/PII:016372589190051M?httpAccept=text/plain

8 November 2022

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Pharmacology & Therapeutics

8 November 2022

published in

1 reference

15 August 2017

volume

50

1 reference

15 August 2017

issue

3

1 reference

15 August 2017

page(s)

367-424

1 reference

Why is 5-fluorouracil a mutagen?

15 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Locoregional application of 5-fluorouracil to the liver: alteration of pharmacokinetics and bone marrow toxicity in rats with thioacetamide-induced cirrhosis

8 November 2022

3

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Enzymes of salvage and de novo pathways of synthesis of pyrimidine nucleotides in human colorectal adenocarcinomas

8 November 2022

4

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

A randomized comparison of doxifluridine and fluorouracil in colorectal carcinoma

8 November 2022

5

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Epidermal growth factor receptor-mediated selective cytotoxicity of antitumor agents toward human xenografts and murine syngeneic solid tumors

8 November 2022

6

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Combined 5-fluorouracil and floxuridine administered as a 14-day infusion. A phase I study

8 November 2022

8

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Five years clinical experience with 5-fluorouracil

8 November 2022

9

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

A phase III study comparing the clinical utility of four regimens of 5-Fluorouracil.A preliminary report

8 November 2022

10

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Selective enhancement of 5-fluorouridine uptake and action in rat hepatomas in vivo following pretreatment with D-galactosamine and 6-azauridine or N-(phosphonacetyl)-L-aspartate

8 November 2022

11

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

In vivo inactivation by acivicin of carbamoyl-phosphate synthetase II in rat hepatoma

8 November 2022

12

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer

8 November 2022

13

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

A phase II trial of 5-fluorouracil, doxorubicin, mitomycin C, and leucovorin in advanced gastric carcinoma

8 November 2022

14

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Tumor 5-fluorodeoxyuridylate concentration as a determinant of 5-fluorouracil response

8 November 2022

15

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Mechanisms of sensitivity and resistance of murine tumors to 5-fluorouracil

8 November 2022

16

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers

8 November 2022

17

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Mechanism of cytotoxic activity of 5?-deoxy-5-fluorouridine

8 November 2022

21

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Reversal of adenine toxicity by pyrimidine mucleosides

8 November 2022

24

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Disposition and availability of 5-fluorouracil prodrug 5'-deoxy-5-fluorouridine after oral administration in rats

8 November 2022

25

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas

8 November 2022

26

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Letter: 5-iodoacetamidomethyl-2'-deoxyuridine 5'-phosphate. A selective inhibitor of mammalian thymidylate synthetases

8 November 2022

29

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Experiments on the efficacy and toxicity of locoregional chemotherapy of liver tumors with 5-fluoro-2'-deoxyuridine (FUDR) and 5-fluorouracil (5-FU) in an animal model

8 November 2022

30

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Experimental chemotherapy of neuroblastoma. II. Increased thymidylate synthetase activity in a 5-fluorodeoxyuridine-resistant variant of mouse neuroblastoma

8 November 2022

31

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Synergistic interaction in Jensen tumor cells of two modes of exposure to inosine that potentiate the cytotoxicity of 5-fluorouracil

8 November 2022

32

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Disposition and metabolism of 1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) in humans

8 November 2022

33

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Thymidine enhancement of methotrexate and 5-fluorouracil toxicity in cultured human colon carcinoma

8 November 2022

34

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Lack of interference by the unnatural isomer of 5-formyltetrahydrofolate with the effects of the natural isomer in leucovorin preparations

8 November 2022

38

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

New vistas for leucovorin in cancer chemotherapy

8 November 2022

39

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Effect of very high-dose thymidine infusions on leukemia and lymphoma patients

8 November 2022

40

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Continuous 5-day regional chemotherapy by 5-fluorouracil in colon carcinoma: pharmacokinetic evaluation

8 November 2022

42

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Comparison of the sensitivity of hematopoietic colony-forming cells in different proliferative states to 5-fluorouracil

8 November 2022

43

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma

8 November 2022

45

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Enhanced 5-Fluorouracil Nucleotide Formation After Methotrexate Administration: Explanation for Drug Synergism

8 November 2022

47

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

The role of deoxyuridine triphosphate nucleotidohydrolase, uracil-DNA glycosylase, and DNA polymerase alpha in the metabolism of FUdR in human tumor cells

8 November 2022

48

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Effect of 5-fluorouracil on the synthesis and translation of polyadenylic acid-containing RNA from regenerating rat liver

8 November 2022

49

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Augmentation by thymidine of the incorporation and distribution of 5-fluorouracil in ribosomal RNA

8 November 2022

50

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Continuous cisplatin (24-hour) and 5-fluorouracil (120-hour) infusion in recurrent head and neck squamous cell carcinoma

8 November 2022

55

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Comparison of the pyrimidine nucleoside phosphorylase activity in human tumors and normal tissues

8 November 2022

56

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Uridine kinase: properties, biological significance and chemotherapeutic aspects (a review)

8 November 2022

58

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Development of a trichloroacetic acid precipitation assay for covalent adducts of thymidylate synthase

8 November 2022

59

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

THE MODE OF ACTION OF 5-FLUOROURACIL AND ITS DERIVATIVES

8 November 2022

62

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Pharmacokinetics of 5-fluorouracil infusions in the rat: comparison with man and other species

8 November 2022

64

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes

8 November 2022

65

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosides

8 November 2022

69

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Role of ribonucleotide reductase in cell division

8 November 2022

70

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Evidence for role of purine nucleoside phosphorylase in sensitivity of Novikoff hepatoma cells to 5-fluorouracil

8 November 2022

71

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Effect of 5-fluorouracil on RNA metabolism in Novikoff hepatoma cells

8 November 2022

72

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Nucleosides. XLIV. Long-range proton-fluorine spin-spin coupling in 5-fluoropyrimidine nucleosides

8 November 2022

77

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Enhancement of 5-fluorouracil antitumor effects by the prior administration of methotrexate

8 November 2022

79

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Studies on the mechanism of fluoropyrimidine cytotoxicity in l1210 cells: correlation with inhibition of thymidylate synthetase but not with incorporation into RNA.

8 November 2022

80

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Fluorinated pyrimidines as tight-binding inhibitors of thymidylate synthetase

8 November 2022

82

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Chemotherapy of large bowel cancer

8 November 2022

86

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Non-linear pharmacokinetics of 5-fluorouracil as described by in vivo behaviour of 5,6 dihydro-5-fluorouracil

8 November 2022

87

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Interactions of methotrexate and cyclophosphamide with the pharmacokinetics of 5-fluorouracil in an animal model

8 November 2022

88

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Galactosamine hepatitis: key role of the nucleotide deficiency period in the pathogenesis of cell injury and cell death

8 November 2022

91

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Effects of 5-fluorouracil and 6-azauracil on the synthesis of ribonucleic acid and protein in Saccharomyces carlsbergensis

8 November 2022

92

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Rapid in vivo inactivation by acivicin of CTP synthetase, carbamoyl-phosphate synthetase II, and amidophosphoribosyltransferase in hepatoma

8 November 2022

93

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Dihydrofluorouracil, a fluorouracil catabolite with antitumor activity in murine and human cells

8 November 2022

95

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

The molecular basis for the differential sensitivity of B and T lymphocytes to growth inhibition by thymidine and 5-fluorouracil

8 November 2022

102

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Modulation of 5-fluorouracil toxicity by uridine, deoxyuridine, orotate and dipyridamole in normal tissues of rats with liver adenocarcinoma

8 November 2022

103

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Circadian rhythm of hepatic uridine phosphorylase activity and plasma concentration of uridine in mice

8 November 2022

104

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites

8 November 2022

105

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Interferon effects upon fluorouracil metabolism by HL-60 cells

8 November 2022

106

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice

8 November 2022

107

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Enhancement of the sensitivity of human colon cancer cells to growth inhibition by acivicin achieved through inhibition of nucleic acid precursor salvage by dipyridamole

8 November 2022

110

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Effects of 5-fluorouracil on base modification in Escherichia coli tRNA

8 November 2022

111

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Kinetics and Mechanisms of Drug Action on Microorganisms XXIII: Microbial Kinetic Assay for Fluorouracil in Biological Fluids and Its Application to Human Pharmacokinetics

8 November 2022

114

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Reverse-phase liquid chromatography of 5-fluorouracil nucleosides and nucleotides in the presence of quaternary ammonium ions

8 November 2022

115

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Analysis of the effect of 5-fluorouracil on the synthesis and translation of polysomal poly(A)RNA from Ehrlich ascites cells

8 November 2022

116

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Association of cell lethality with incorporation of 5-fluorouracil and 5-fluorouridine into nuclear RNA in human colon carcinoma cells in culture

8 November 2022

118

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

The effect of 5-fluorouracil on the synthesis of nuclear RNA in L1210 cells in vitro

8 November 2022

119

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Biological consequences of incorporation of 5-fluorocytidine in the RNA of 5-fluorouracil-treated eukaryotic cells

8 November 2022

120

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: a randomized trial

8 November 2022

121

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma: a randomized comparison of two regimens

8 November 2022

122

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

On the action of fluorouracil on leukemia cells

8 November 2022

123

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Toxicity of levamisole and 5-fluorouracil in human colon carcinoma cells

8 November 2022

125

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Augmentation of 5-fluorouracil cytotoxicity in human colon cancer cells by dipyridamole

8 November 2022

126

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Alteration of fluorouracil metabolism in human colon cancer cells by dipyridamole with a selective increase in fluorodeoxyuridine monophosphate levels

8 November 2022

127

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Modulation of fluorouracil metabolism and cytotoxicity by nitrothiobenzylinosine

8 November 2022

128

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Enhancement of 5-fluorouracil's anticancer activity by dipyridamole

8 November 2022

129

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Interaction of deoxyuridine with fluorouracil and dipyridamole in a human colon cancer cell line

8 November 2022

131

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

The Pharmacology of Prodrugs of 5-Fluorouracil and 1-β-D-Arabinofuranosylcytosine

8 November 2022

133

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Effects of fluorouracil on RNA synthesis in Bacillus cereus

8 November 2022

134

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Pyrimidine nucleoside monophosphate kinase from human leukemic blast cells

8 November 2022

136

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Circadian variation of 5-fluorouracil catabolism in isolated perfused rat liver

8 November 2022

139

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

The performance of microparticle chemically-bonded anion-exchange resins in the analysis of nucleotides

8 November 2022

142

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Improved assay method of dTMP synthase in rat liver and its application to human lung cancer cells

8 November 2022

143

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Fluorinated Pyrimidines and Their Nucleosides

8 November 2022

145

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Fluorinated pyrimidines, a new class of tumour-inhibitory compounds

8 November 2022

146

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Fluorinated Pyrimidines and Their Nucleosides

8 November 2022

147

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Mutagenesis of bacteriophage PBS 2

8 November 2022

149

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Increased formation of nucleotide derivatives of 5-fluorouridine in hepatoma cells treated with inhibitors of pyrimidine synthesis and D-galactosamine

8 November 2022

152

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Preventive effects of 5-fluorouridine and uridine on d-galactosamine-induced liver injury

8 November 2022

154

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Characterization of the fluorodihydrouracil substituent in 5-fluorouracil-containing Escherichia coli transfer RNA.

8 November 2022

157

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice

8 November 2022

158

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Relationship between 5-fluoro-2'-deoxyuridylate, 2'-deoxyuridylate, and thymidylate synthase activity subsequent to 5-fluorouracil administration, in xenografts of human colon adenocarcinomas

8 November 2022

159

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Determination of thymidylate synthase activity in colon tumor tissues after treatment with 5-fluorouracil

8 November 2022

160

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Characterization of the pools of 5,10-methylenetetrahydrofolates and tetrahydrofolates in xenografts of human colon adenocarcinoma

8 November 2022

161

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Comparison of the conversion of 5-formyltetrahydrofolate and 5-methyltetrahydrofolate to 5,10-methylenetetrahydrofolates and tetrahydrofolates in human colon tumors

8 November 2022

162

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

More evidence for circadian rhythm effects in cancer chemotherapy: the fluoropyrimidine story

8 November 2022

164

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Purineless death as a link between growth rate and cytotoxicity by methotrexate

8 November 2022

165

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Mechanism of potentiation of antitumor activity of 5-fluorouracil against adenocarcinoma 755 by L-cysteine

8 November 2022

169

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Effect of pyrimidines, purines and their nucleosides on antitumor activity of 5-fluorouracil against L-1210 leukemia

8 November 2022

170

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Relationship between antitumor effect and metabolites of 5-fluorouracil in combination treatment with 5-fluorouracil and guanosine in ascites sarcoma 180 tumor system

8 November 2022

171

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Mechanism of potentiation of antitumor activity of 5-fluorouracil by guanine ribonucleotides against adenocarcinoma 755

8 November 2022

172

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil against adenocarcinoma 755 in mice. Increased therapeutic index and correlation with increased plasma 5-fluorouracil levels

8 November 2022

173

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Enhanced antitumor effect of 5'-deoxy-5-fluorouridine by oral administration with L-cysteine.

8 November 2022

175

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with radiation therapy in mice bearing colon 26 adenocarcinoma.

8 November 2022

177

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Effects of 5-fluorouracil on globin mRNA synthesis in murine erythroleukemia cells

8 November 2022

178

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Effect of intracellular folate concentration on the modulation of 5-fluorouracil cytotoxicity by the elevation of phosphoribosylpyrophosphate in cultured human KB cells

8 November 2022

183

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Complex inhibition of thymidylate synthetase by aromatic diamidines: evidence for both rapid, freely reversible and slowly progressive, nonequilibrium inhibition

8 November 2022

184

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Pharmacokinetics of 5-fluorouracil in rabbits in experimental regional chemotherapy

8 November 2022

185

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Continuous intrahepatic infusion of floxuridine and leucovorin through an implantable pump for the treatment of hepatic metastases from colorectal carcinoma

8 November 2022

187

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Effects of acivicin and PALA, singly and in combination, on de novo pyrimidine biosynthesis

8 November 2022

188

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Aspartate carbamoyltransferase inhibition and uridylate trapping result in a synergistic depression of uridine triphosphate in hepatoma cells

8 November 2022

190

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Uridine triphosphate deficiency, growth inhibition, and death in ascites hepatoma cells induced by a combination of pyrimidine biosynthesis inhibition with uridylate trapping

8 November 2022

191

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

The trapping of uridine phosphates by D-galactosamine. D-glucosamine, and 2-deoxy-D-galactose. A study on the mechanism of galactosamine hepatitis

8 November 2022

193

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Uridylate-trapping sugar analogs in combination with inhibitors of uridylate synthesis de novo and 5-fluorouridine

8 November 2022

194

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Potentiation of antimetabolite action by uridylate trapping

8 November 2022

195

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Cell surface alterations associated with exposure of leukemia L1210 cells to fluorouracil

8 November 2022

196

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Influence of ribose donors on the action of 5-fluorouracil

8 November 2022

197

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells

8 November 2022

198

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in a Phase I trial

8 November 2022

200

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck

8 November 2022

201

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil

8 November 2022

202

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Effect of concurrent calcium leucovorin infusion on 5-fluorouracil cytotoxicity against murine L1210 leukemia

8 November 2022

204

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors

8 November 2022

206

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Biologic effect of 5-fluoro-2′-deoxyuridine incorporation in L1210 deoxyribonucleic acid

8 November 2022

210

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

"Thymineless" death in androgen-independent prostatic cancer cells

8 November 2022

211

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Effects of pyrimidine nucleoside phosphorylase inhibitors on hepatic fluoropyrimidine elimination in the rat

8 November 2022

212

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Thymidylate synthetase: mechanism of inhibition by 5-fluoro-2'-deoxyuridylate.

8 November 2022

213

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Synergism between 5-fluorouracil and N-methylformamide in HT29 human colon cancer line

8 November 2022

215

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic

8 November 2022

216

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Nuclear magnetic resonance studies of the solution conformation of nucleoside diphosphohexoses and their components

8 November 2022

217

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Combined action of acivicin and D-galactosamine on pyrimidine nucleotide metabolism in hepatoma cells

8 November 2022

220

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity

8 November 2022

221

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

The effect of sequential methotrexate and 5-fluorouracil in patients with recurrent head and neck cancer

8 November 2022

222

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Biochemical factors affecting the tightness of 5-fluorodeoxyuridylate binding to human thymidylate synthetase

8 November 2022

223

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Fluorouracil and recombinant human interferon alfa-2a in the treatment of metastatic chemotherapy-refractory urothelial tumors

8 November 2022

224

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

The increased cytotoxicity in colon adenocarcinoma of methotrexate-5-fluorouracil is not associated with increased induction of lesions in DNA by 5-fluorouracil

8 November 2022

226

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Progressive formation of DNA lesions during treatment with anti-metabolites without incorporation of the drugs into DNA

8 November 2022

227

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Increased levels of DNA lesions induced by leucovorin-5-fluoropyrimidine in human colon adenocarcinoma

8 November 2022

228

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Effects of 5-fluorouridine on modified nucleosides in mouse liver transfer RNA

8 November 2022

230

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid

8 November 2022

233

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

A spectrophotometric method for detection of 5'-fluorouracil in plasma

8 November 2022

234

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

5-Fluorouracil and UFT-sensitive gastric carcinoma has a high level of thymidylate synthase

8 November 2022

236

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

On the nature of a sparing effect by thymidine on the utilization of deoxycytidine

8 November 2022

240

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

8 November 2022

An overview of thymidine

243

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Failure of high-dose leucovorin to improve therapy with the maximally tolerated dose of 5-fluorouracil: a murine study with clinical relevance?

8 November 2022

245

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine

8 November 2022

246

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Uridine sugar nucleotides modified in their nucleoside moieties and their effect on lipid-linked saccharide formation in vitro

8 November 2022

249

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Enzymatic synthesis and function of folylpolyglutamates

8 November 2022

250

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Prediction of 5-fluorouracil cytotoxicity towards the Walker carcinosarcoma using peak integrals of fluoronucleotides measured by MRS in vivo

8 November 2022

251

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Cytotoxic effects of hyperthermia, 5-fluorouracil and their combination on a human leukemia T-lymphoblast cell line, CCRF-CEM.

8 November 2022

252

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Enhancement of the antitumor effects of 5-fluorouracil by folinic acid

8 November 2022

254

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Enzymatic cleavage of various fluorinated pyrimidine nucleosides to 5-fluorouracil and their antiproliferative activities in human and murine tumor cells

8 November 2022

255

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Hematologic Effects of Interleukin-1β, Granulocyte Colony-Stimulating Factor, and Granulocyte-Macrophage Colony-Stimulating Factor in Tumor-bearing Mice Treated With Fluorouracil

8 November 2022

258

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase

8 November 2022

259

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate

8 November 2022

262

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Effects of thymidine and thymidine plus 5-fluorouracil on the growth kinetics of a human lymphoid cell line

8 November 2022

265

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Biochemical determinants of 5-fluorouracil response in vivo. The role of deoxyuridylate pool expansion

8 November 2022

268

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Enzymes of uracil catabolism in normal and neoplastic human tissues

8 November 2022

269

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Pyrimidine acyclonucleosides, inhibitors of uridine phosphorylase

8 November 2022

272

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

5-benzylacyclouridine and 5-benzyloxybenzylacyclouridine, potent inhibitors of uridine phosphorylase

8 November 2022

273

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study

8 November 2022

274

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Fluorouracil therapy of intraocular Greene melanoma in the rabbit

8 November 2022

277

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Potentiation of the chemotherapeutic action of 5-fluorouracil by combination with cytidine or guanosine on HRS-Sarcoma

8 November 2022

278

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Studies on uridine-diphosphate-glucose

8 November 2022

279

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

The role of drug sequence in therapeutic selectivity of the combination of 5-fluorouracil and cis-platin

8 November 2022

280

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

8 November 2022

Freiburg im Breisgau

284

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Separation of 5-fluorouracil and uracil by ion-pair reversed-phase high-performance liquid chromatography on a column with porous polymeric packing

8 November 2022

285

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Separation of several 5-fluorouracil metabolites in various melanoma cell lines. Evidence for the synthesis of 5-fluorouracil-nucleotide sugars

8 November 2022

286

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Toxicity and antitumor effect of 5-fluorouracil and its rescue by uridine

8 November 2022

288

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Purine nucleosides as cell-specific modulators of 5-fluorouracil metabolism and cytotoxicity

8 November 2022

289

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Diurnal variation in the therapeutic efficacy of 5-fluorouracil against murine colon cancer

8 November 2022

290

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

In vitro biochemical and in vivo biological studies of the uridine 'rescue' of 5-fluorouracil

8 November 2022

291

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Enhanced therapeutic efficacy of 5'deoxy-5-fluorouridine in 5-fluorouracil resistant head and neck tumours in relation to 5-fluorouracil metabolising enzymes

8 November 2022

292

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Do antimetabolites interfere with the glycosylation of cellular glycoconjugates?

8 November 2022

295

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa

8 November 2022

296

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients

8 November 2022

298

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma

8 November 2022

299

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Fluorouracil: biochemistry and pharmacology

8 November 2022

300

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Uridine transport in novikoff rat hepatoma cells and other cell lines and its relationship to uridine phosphorylation and phosphorolysis

8 November 2022

302

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Facilitated transport of inosine and uridine in cultured mammalian cells is independent of nucleoside phosphorylases

8 November 2022

303

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Model studies of the thymidylate synthetase reaction. Nucleophilic displacement of 5-p-nitrophenoxymethyluracils.

8 November 2022

304

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Methods for the complete analysis of 5-fluorouracil metabolites in cell extracts

8 November 2022

305

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Sequence dependence of the antitumor and toxic effects of 5-fluorouracil and cis-diamminedichloroplatinum combination on primary colon tumors in mice

8 November 2022

306

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

In vivo 19F NMR spectroscopy of the antimetabolite 5-fluorouracil and its analogues. An assessment of drug metabolism

8 November 2022

307

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Inhibition of transfer RNA function by replacement of uridine and uridine-derived nucleosides with 5-fluorouridine

8 November 2022

309

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Catalytic function of thymidylate synthase is confined to S phase due to its association with replitase

8 November 2022

310

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Inhibitor evidence for allosteric interaction in the replitase multienzyme complex

8 November 2022

311

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

The inhibition of gamma-glutamyl transpeptidase and glutathione metabolism of isolated rat kidney cells by L-(alpha S, 5S)-alpha-amino-3-chloro-4, 5-dihydro-5-isoxazoleacetic acid (AT-125; NSC-163501)

8 November 2022

312

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion

8 November 2022

315

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

The synthesis of 5-fluorouridine 5'-phosphate by a pyrimidine phosphoribosyltransferase of mammalian origin. I. Some properties of the enzyme from P1534J mouse leukemic cells

8 November 2022

316

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Synthesis of 5-fluorouridine 5'-phosphate by a pyrimidine phosphoribosyltransferase of mammalian origin. II. Correlation between the tumor levels of the enzyme and the 5-fluorouracil-promoted increase in survival of tumor-bearing mice

8 November 2022

318

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

8 November 2022

320

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

5-Fluorouracil and mucopeptide biosynthesis by Staphylococcus aureus

8 November 2022

321

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Miscoding caused by 5-fluorouracil

8 November 2022

323

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Studies on unbalanced growth in tissue culture. I. Induction and consequences of thymidine deficiency

8 November 2022

324

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Toxicity and antitumor activity of 5-fluorouracil in combination with leucovorin. Role of dose schedule and route of administration of leucovorin

8 November 2022

325

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Selectivity of action of 5-FU: biochemical basis

8 November 2022

326

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Schedule-dependent antitumor and toxic effects of thymidine and 5-fluorouracil in AKR and L1210 leukemias

8 November 2022

331

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Model studies of thymidylate synthetase. Neighboring-group facilitation of electrophilic substitution reactions of uracil furanosides

8 November 2022

332

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate.

8 November 2022

334

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

The 1985 Walter Hubert lecture. Malignant cell differentiation as a potential therapeutic approach

8 November 2022

335

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Effects of A-methopterin on the purine biosynthesis of susceptible and resistant TA3 ascites cells

8 November 2022

336

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Incorporation of 5-fluorouracil into murine bone marrow DNA in vivo

8 November 2022

337

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Effect of Uridine on the Metabolism of 5-Fluorouracil in the CD8F 1 Murine Mammary Carcinoma System

8 November 2022

338

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Quantitation of 5-fluorouracil incorporation into RNA by high-performance liquid chromatography without the use of radioactive precursors

8 November 2022

340

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells

8 November 2022

341

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice

8 November 2022

342

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Treatment of patients with advanced colorectal cancer with cisplatin, 5-fluorouracil, and leucovorin

8 November 2022

343

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Clinical pharmacology of the stereoisomers of leucovorin during repeated oral dosing

8 November 2022

344

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models

8 November 2022

345

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

5-Fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity

8 November 2022

347

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma

8 November 2022

348

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

19F magnetic resonance spectroscopy studies of the metabolism of 5-fluorouracil in murine RIF-1 tumors and liver

8 November 2022

354

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Enzymic ribosidation and ribotidation of 5-fluorouracil by extracts of the Ehrlich-ascites tumor

8 November 2022

356

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Evidence from rat hepatocytes of an unrecognized pathway of 5-fluorouracil metabolism with the formation of a glucuronide derivative

8 November 2022

359

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Modulation of 5-fluorouracil catabolism in isolated rat hepatocytes with enhancement of 5-fluorouracil glucuronide formation

8 November 2022

360

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Improving the anti-tumor activity of 5-fluorouracil by increasing its incorporation into RNA via metabolic modulation

8 November 2022

365

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Polar solvents: a novel class of antineoplastic agents

8 November 2022

366

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Modulation of 5-fluorouracil-induced toxicity in mice with interferon or with the interferon inducer, polyinosinic-polycytidylic acid

8 November 2022

368

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Failure of L-histidinol to improve the therapeutic efficiency of 5-fluorouracil against murine breast tumors

8 November 2022

369

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Metabolism of 5-fluorouracil to an N-cholyl-2-fluoro-beta-alanine conjugate: previously unrecognized role for bile acids in drug conjugation

8 November 2022

371

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Precursor-dependent differences in the incorporation of fluorouracil in RNA

8 November 2022

373

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles

8 November 2022

375

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Enhanced accumulation of 5-fluorouracil in human tumors in athymic mice by co-administration of Ftorafur and uracil

8 November 2022

376

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Activation by 5-phosphoribosyl 1-pyrophosphate of glutamine-dependent carbamyl phosphate synthetase from mouse spleen

8 November 2022

378

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts

8 November 2022

379

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Mechanisms of potentiation of antitumor activity of 5-fluorouracil by ribothymidine in a mouse tumor system

8 November 2022

380

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

The Mechanism of an Osmotic Instability Induced in E. coli K-12 by 5-Fluorouracil*

8 November 2022

383

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial

8 November 2022

385

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Role of administration route in the therapeutic efficacy of doxifluridine

8 November 2022

387

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Specific inhibition of transfer RNA methylation and modification in tissues of mice treated with 5-fluorouracil

8 November 2022

389

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Enhancement of antitumor effects of 1-hexylcarbamoyl-5-fluorouracil combined with hyperthermia on Ehrlich ascites tumor in vivo and Nakahara-Fukuoka sarcoma cell in vitro

8 November 2022

390

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Effects of uridine and thymidine on the degradation of 5-fluorouracil, uracil, and thymine by rat liver dihydropyrimidine dehydrogenase

8 November 2022

391

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Transport and intracellular metabolism of fluorinated pyrimidines in cultured cell lines

8 November 2022

394

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

8 November 2022

5-Fluorouracil (FUra)

398

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group

8 November 2022

400

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Reversal of 5-fluorouracil-induced myelosuppression by prolonged administration of high-dose uridine

8 November 2022

402

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer

8 November 2022

405

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review

8 November 2022

407

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Histidinol-mediated enhancement of the specificity of two anticancer drugs in mice bearing leukemic bone marrow disease

8 November 2022

408

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Comparison of 5-fluorouracil metabolism in two human gastrointestinal tumor cell lines

8 November 2022

409

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

30 years of 5-fluorouracil

8 November 2022

410

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Biochemical strategy of the genome as expressed in regulation of pyrimidine metabolism

8 November 2022

413

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Biochemical commitment to replication in cancer cells.

8 November 2022

414

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Multi-enzyme-targeted chemotherapy by acivicin and actinomycin

8 November 2022

415

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Separation and analysis of 4'-epimeric UDP-sugars by borate high-performance liquid chromatography

8 November 2022

418

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Substrate properties of 5-fluorouridine diphospho sugars detected in hepatoma cells

8 November 2022

419

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Leukotriene C4 metabolism by hepatoma cells deficient in the uptake of cysteinyl leukotrienes

8 November 2022

421

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

The inhibition of ribosomal RNA synthesis and maturation in Novikoff hepatoma cells by 5-fluorouridine

8 November 2022

426

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Polyacrylamide-Agarose Electrophoretic Pattern of the RNA Labelling in Liver Cytoplasm and Total Liver of 5-Fluorouracil Treated Rats

8 November 2022

427

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage

8 November 2022

428

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonoacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal cancer

8 November 2022

430

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells

8 November 2022

431

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation

8 November 2022

432

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Active Transport of 5-Fluorouracil and Its Energy Coupling in Ehrlich Ascites Tumor Cells1

8 November 2022

435

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

Intraarterial infusion of 5-fluoro-2-deoxyuridine-C8 dissolved in a lymphographic agent in malignant liver tumors. A preliminary report

8 November 2022

436

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

The mechanism of dNTP-unbalanced cell death induced by 5-fluorouracil and its derivatives

8 November 2022

439

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90051-M

8 November 2022

Identifiers

1 reference

15 August 2017

1 reference